Adv Mat Tech:科学家研发出纸质版“即时诊断工具”

2017-08-24 Flora 生物探索

近日,来自于普渡大学的科学家们推出一款新型的医疗检测设备——完全由纸制成,利用电化学方法分析生物标志物,通过纸张颜色变化反馈检测结果,实现疾病诊疗的目的。


一种新型的纸质版医学诊断设备(图片来源:普渡大学)

近日,来自于普渡大学的科学家们推出一款新型的医疗检测设备——完全由纸制成,利用电化学方法分析生物标志物,通过纸张颜色变化反馈检测结果,实现疾病诊疗的目的。

这一自我供电、纸质版诊断装置(self-powered,paper-based electrochemical devices,SPEDs)可以与便携式恒电位仪相连,实现自我供电、自动化检测过程,便于患者自己操作。它的设计定位是“即时诊断工具”。

普渡大学的工业和生物医学工程助理教授Ramses V. Martinez将这一设备比喻成一个“便携式实验室”,并不需要水电或者其他的高端设备。他和团队希望该检测装置可以服务于偏远地区或者军事基地的人,便于他们自行检测疾病。相关研究成果于8月22日发表在《Advanced Materials Technologies》期刊。

根据视频展示,SPEDs的表层由未经处理的纤维素纸构建血液样本的检测通道,共设置了4个电化学检测区域和10个比色分析区域。这些“微流控通道”允许精准的检测,且通过颜色的变化反馈特定的检测结果。

为了准确读取颜色信息,研究团队开发了一个机器视觉算法,用于自动识别和量化10个比色分析区域的颜色变化。通过手机拍照功能获取颜色图像,借助算法程序分析颜色变化背后的病理信息,从而为快速提供诊断结果创造了可能,并有望与远程医疗结合。

SPEDs的底层是一个“摩擦发电机”或者热电发生器(TEG),通过摩擦或者挤压产生运行诊断检测所必须的电流。为了便于使用,研究人员设计一个廉价的手持装置——恒电位仪,它可以与SPED简易连接,便于患者自行检测。

SPEDs有着低成本、轻便、灵活和便于快速使用的特点,其具体的检测过程:将患者的血液点滴至设备的圆形区域,或者将SPEDs的“自我移液检测区域”直接浸入样本中。随后,SPEDs(血液样本分析)+便携式恒电位仪(供电)+机器视觉算法(识别颜色编码的信息)的组合,即可实现诊断过程。

SPEDs可以执行“多路复用”(multiplexed)的分析任务,即检测多种生物标志物,例如葡萄糖、尿酸、乳酸、酮、白细胞等等,这些指标与肾脏功能、营养不良和贫血有关。下一步,研究团队将继续优化这一设备,用于更复杂的检测任务,例如登革热、黄热病、疟疾、艾滋病和肝炎等疾病。

原始出处:

Aniket Pal,Hugo E. Cuellar,Randy Kuang,et al.Self-Powered, Paper-Based Electrochemical Devices for Sensitive Point-of-Care Testing.DOI: 10.1002/admt.201700130

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1652214, encodeId=341e165221475, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Nov 24 10:03:00 CST 2017, time=2017-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300046, encodeId=d6d2130004642, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Aug 26 11:03:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237322, encodeId=4d6323e32262, content=谢谢分享谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Aug 26 09:19:15 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237321, encodeId=558c23e3214d, content=谢谢分享谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Aug 26 09:19:07 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723629, encodeId=ccf51e236290a, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Wed Apr 18 15:03:00 CST 2018, time=2018-04-18, status=1, ipAttribution=)]
    2017-11-24 shock_melon
  2. [GetPortalCommentsPageByObjectIdResponse(id=1652214, encodeId=341e165221475, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Nov 24 10:03:00 CST 2017, time=2017-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300046, encodeId=d6d2130004642, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Aug 26 11:03:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237322, encodeId=4d6323e32262, content=谢谢分享谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Aug 26 09:19:15 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237321, encodeId=558c23e3214d, content=谢谢分享谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Aug 26 09:19:07 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723629, encodeId=ccf51e236290a, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Wed Apr 18 15:03:00 CST 2018, time=2018-04-18, status=1, ipAttribution=)]
    2017-08-26 lqvr
  3. [GetPortalCommentsPageByObjectIdResponse(id=1652214, encodeId=341e165221475, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Nov 24 10:03:00 CST 2017, time=2017-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300046, encodeId=d6d2130004642, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Aug 26 11:03:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237322, encodeId=4d6323e32262, content=谢谢分享谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Aug 26 09:19:15 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237321, encodeId=558c23e3214d, content=谢谢分享谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Aug 26 09:19:07 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723629, encodeId=ccf51e236290a, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Wed Apr 18 15:03:00 CST 2018, time=2018-04-18, status=1, ipAttribution=)]
    2017-08-26 明天会更好!

    谢谢分享谢谢分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1652214, encodeId=341e165221475, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Nov 24 10:03:00 CST 2017, time=2017-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300046, encodeId=d6d2130004642, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Aug 26 11:03:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237322, encodeId=4d6323e32262, content=谢谢分享谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Aug 26 09:19:15 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237321, encodeId=558c23e3214d, content=谢谢分享谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Aug 26 09:19:07 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723629, encodeId=ccf51e236290a, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Wed Apr 18 15:03:00 CST 2018, time=2018-04-18, status=1, ipAttribution=)]
    2017-08-26 明天会更好!

    谢谢分享谢谢分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1652214, encodeId=341e165221475, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Nov 24 10:03:00 CST 2017, time=2017-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300046, encodeId=d6d2130004642, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Aug 26 11:03:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237322, encodeId=4d6323e32262, content=谢谢分享谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Aug 26 09:19:15 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237321, encodeId=558c23e3214d, content=谢谢分享谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Aug 26 09:19:07 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723629, encodeId=ccf51e236290a, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Wed Apr 18 15:03:00 CST 2018, time=2018-04-18, status=1, ipAttribution=)]

相关资讯

抗体药物研发ABC

近年来,小分子类重磅药物专利进入到期潮,在小分子新药开发日益困难的大背景下,以抗体类药物为代表的生物技术药物的研发异军突起。根据汤森路透的数据,目前已获批或至少进入Ⅲ期临床研究的抗体类药物共有243个,其中114种品种已经获批。243个抗体类药物中,有163个属于创新药,另有80个是生物类似物。随着政府全面布局“精准医药”,靶向药物和免疫药物为代表的新一代药物正在改变包括癌症在内的多种疑难疾病的治

1年内72种儿童药被国家纳入鼓励研发清单,有望缓解用药荒

“把一片成人标准的药片分成1/2片、1/4片,甚至1/8片,便是儿童片剂。”这种常见的对儿科用药的误解——“儿童就是小大人”,其实反映了中国“儿童药短缺”的现实。据全国工商联药业商会统计显示,我国现有约6000多家制药企业,仅10多家制药企业专门生产儿童用药。此外,我国90%的药品没有“儿童版”。2016年9月,由国家食品药品监督管理总局南方医药经济研究所发布的《2016年儿童用药安全调查报告白皮

226家药企研发费用曝光!

医药地方台根据同花顺数据统计,有226家药企发布了2016年研发费用总额。其中,有2家药企研发费用破10亿元,分别是恒瑞医药(11.8435亿元)、复星医药(11.0612亿元)。

创新研发医疗器械进入临床,要开“绿灯”

国家鼓励加快医疗器械的创新研发,然而创新型医疗器械进入临床使用仍然面临不少现有体制和政策上的障碍。

陈凯先院士:基因编辑技术对促进新药研发具有重大价值

6月27日,由《药学进展》编辑委员会、中国药科大学、中国药学会共同主办,复星医药、恒瑞医药、先声药业联合承办的《药学进展》编委会暨“第三届药学前沿高峰论坛”在上海隆重召开。包含多位院士、产业领袖、政界精英、临床权威在内的强大嘉宾阵容吸引了数百名与会者。

从辉瑞、罗氏等外企出走的研发大佬,如今都去哪儿了?

3月31日,原新基公司全球临床研究与开发部门执行总监梅建明结束了他在新基的最后一个工作日,开始全力投入德琪医药科技有限公司的创业。 这是最新一条关于跨国药企研发带头人离职选择自主创业的消息,契机则是中国当前阶段对于创新药审评审批制度的改善。